{
    "clinical_study": {
        "@rank": "166553", 
        "arm_group": [
            {
                "arm_group_label": "Androxal 12.5 mg Formulation A Crossover B", 
                "arm_group_type": "Experimental", 
                "description": "Androxal capsules, 12.5 mg, once a day for one day for each formulation"
            }, 
            {
                "arm_group_label": "Androxal 25 mg Formulation A Crossover B", 
                "arm_group_type": "Experimental", 
                "description": "Androxal 25 mg, capsules, one a day for one day for each formulation"
            }
        ], 
        "brief_summary": {
            "textblock": "To determine and compare the pharmacokinetics (PK) of a single dose of each of two\n      formulations of 12.5 mg and 25 mg Androxal administered to healthy male volunteers, and to\n      determine and compare the safety of a single dose each of two formulations of 12.5 mg and 25\n      mg Androxal administered to healthy male volunteers."
        }, 
        "brief_title": "Comparison of Two Formulations of Androxal", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Bioequivalence", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Speaks, reads, and understands English or Spanish and is willing and able to provide\n             written informed consent on an Institutional Review Board (IRB)-approved form prior\n             to the initiation of any study procedures;\n\n          -  Male, between the ages of 18-60 years;\n\n          -  No significant abnormal findings at the screening physical examination as evaluated\n             by the Investigator;\n\n          -  Normal laboratory values (or abnormal but not clinically significant) at screening as\n             determined by the Investigator;\n\n          -  Subject is willing to remain in the clinic overnight for the Day 1 and Day 6 visits;\n\n          -  Must be able to swallow gelatin capsules\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity to Clomid;\n\n          -  Abnormal screening visit vital signs or clinical laboratory evaluation considered\n             clinically significant by the Investigator;\n\n          -  Subject with a significant organ abnormality or disease as determined by the\n             Investigator;\n\n          -  Any medical condition that would interfere with the study as determined by the\n             Investigator;\n\n          -  Slow Cytochrome P4502D6 (CYP2D6) metabolizer\n\n          -  Participation in a clinical trial with investigational medication within 30 days\n             prior to study medication administration;\n\n          -  An acute illness within 5 days of study medication administration;;\n\n          -  A mental condition rendering the subject unable to understand the nature, scope, and\n             possible consequences of the study and/or evidence of an uncooperative attitude, as\n             determined by the Investigator;\n\n          -  History of venous thromboembolic disease (e.g. deep vein thrombosis or pulmonary\n             embolism);\n\n          -  History of myocardial infarction, unstable angina, symptomatic heart failure,\n             ventricular dysrhythmia, or known history of (corrected QT)QTc interval prolongation;\n\n          -  An employee or family member of an employee of the study site or the Sponsor."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01984398", 
            "org_study_id": "ZA-110"
        }, 
        "intervention": [
            {
                "arm_group_label": "Androxal 12.5 mg Formulation A Crossover B", 
                "intervention_name": "Androxal 12.5 mg Formulation A", 
                "intervention_type": "Drug", 
                "other_name": "enclomiphene citrate"
            }, 
            {
                "arm_group_label": "Androxal 12.5 mg Formulation A Crossover B", 
                "intervention_name": "Androxal 12.5 mg Formulation B", 
                "intervention_type": "Drug", 
                "other_name": "enclomiphene citrate"
            }, 
            {
                "arm_group_label": "Androxal 25 mg Formulation A Crossover B", 
                "intervention_name": "Androxal 25 mg Formulation A", 
                "intervention_type": "Drug", 
                "other_name": "enclomiphene citrate"
            }, 
            {
                "arm_group_label": "Androxal 25 mg Formulation A Crossover B", 
                "intervention_name": "Androxal 25 mg Formulation B", 
                "intervention_type": "Drug", 
                "other_name": "enclomiphene citrate"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Clomiphene"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 23, 2014", 
        "link": {
            "description": "Sponsor Corporate Website", 
            "url": "http://www.reprosrx.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Miami", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "30014-3616"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A DOUBLE-BLIND CROSSOVER STUDY IN HEALTHY VOLUNTEERS TO COMPARE TWO FORMULATIONS OF ANDROXAL", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To determine and compare the PK parameter Cmax between two formulations of Androxal", 
            "measure": "Pharmacokinetic Parameter Cmax", 
            "safety_issue": "No", 
            "time_frame": "24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01984398"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Repros Therapeutics Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Repros Therapeutics Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}